Gene Symbol: MIR186
Description: microRNA 186
Alias: MIRN186, miR-186
Species: human
Products:     MIR186

Top Publications

  1. Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N, et al. PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis. 2013;34:2145-55 pubmed publisher
    ..This study identified both PTTG1 and miR-186 as potential anti-invasion targets for therapeutic intervention in NSCLC. ..
  2. Dong Y, Jin X, Sun Z, Zhao Y, Song X. MiR-186 Inhibited Migration of NSCLC via Targeting cdc42 and Effecting EMT Process. Mol Cells. 2017;40:195-201 pubmed publisher
    ..Thus, miR-186 is a potential target for NSCLC therapy. miR-186 is proposed to be one of tumor-suppressors and may serve as a therapeutic target in NSCLC treatment. ..
  3. He W, Feng J, Zhang Y, Wang Y, Zang W, Zhao G. microRNA-186 inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma by targeting SKP2. Lab Invest. 2016;96:317-24 pubmed publisher
    ..Our findings established that the miR-186 has a suppressive role in ESCC progression via SKP2-mediated pathway, and this implies that miR-186 could be a potential therapeutic target for ESCC. ..
  4. Lei G, Kline H, Lee C, Wilkes D, Zhang C. Regulation of Collagen V Expression and Epithelial-Mesenchymal Transition by miR-185 and miR-186 during Idiopathic Pulmonary Fibrosis. Am J Pathol. 2016;186:2310-6 pubmed publisher
  5. Sun K, Jiao J, Chen S, Liu B, Zhao Y. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res. 2015;8:80 pubmed publisher
    ..Our results are the first to demonstrate that miR-186 may sensitize ovarian cancer cell to paclitaxel and cisplatin by targeting ABCB1 and modulating the expression of GST-Ï€. ..
  6. Chang Z, Cui J, Song Y. Long noncoding RNA PVT1 promotes EMT via mediating microRNA-186 targeting of Twist1 in prostate cancer. Gene. 2018;654:36-42 pubmed publisher
    ..Therefore, this study has revealed a novel MECHANISM for the promotion of EMT in prostate cancer by PVT1. Our findings suggest that the PVT1/miR-186/Twist1 regulatory axis may be a new therapeutic target for prostate cancer. ..
  7. Ries J, Baran C, Wehrhan F, Weber M, Neukam F, Krautheim Zenk A, et al. Prognostic significance of altered miRNA expression in whole blood of OSCC patients. Oncol Rep. 2017;37:3467-3474 pubmed publisher
    ..The present study may form the basis for establishing a blood test as a minimally invasive method for the detection of the recurrence of OSCC. ..
  8. Yao Y, Zhang X, Chen H, Li L, Xie W, Lan G, et al. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine ?-lyase in THP-1 macrophages. Atherosclerosis. 2016;250:122-32 pubmed publisher
    ..MicroRNA-186 promotes macrophage lipid accumulation and pro-inflammatory cytokine secretion by targeting cystathionine ?-lyase in THP-1 macrophages. ..
  9. Cui G, Cui M, Li Y, Liang Y, Li W, Guo H, et al. MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells. Tumour Biol. 2014;35:8933-7 pubmed publisher
    ..Furthermore, ROCK1 was inversely correlated with miR-186 expression in NSCLC. Collectively, our data indicate that miR-186 functions as tumor suppressor in NSCLC by targeting ROCK1. ..

More Information


  1. Zhang C, Zhang W, Chen H, Liu C, Wu J, Shi S, et al. Plasma microRNA-186 and proteinuria in focal segmental glomerulosclerosis. Am J Kidney Dis. 2015;65:223-32 pubmed publisher
    ..Last, plasma miR-186, but not miR-125b, level was correlated with degree of proteinuria in patients with FSGS (151 samples). Relatively small cohort size. Plasma miR-186 may be a biomarker for FSGS with nephrotic proteinuria. ..
  2. Wang K, Zhao X, Liu Y, Zeng Q, Mao X, Li S, et al. Circulating MiR-19b-3p, MiR-134-5p and MiR-186-5p are Promising Novel Biomarkers for Early Diagnosis of Acute Myocardial Infarction. Cell Physiol Biochem. 2016;38:1015-29 pubmed publisher
    ..Circulating miR-19b-3p, miR-134-5p and miR-186-5p could be considered promising novel diagnostic biomarkers for the early phase of AMI. ..
  3. Yang J, Yuan D, Li J, Zheng S, Wang B. miR-186 downregulates protein phosphatase PPM1B in bladder cancer and mediates G1-S phase transition. Tumour Biol. 2016;37:4331-41 pubmed publisher
    ..This study has identified PPM1B and miR-186 as potential diagnostic markers in bladder cancer. Promotion of PPM1B and suppression of miR-186 may offer effective therapeutic strategies in the treatment of bladder cancer. ..
  4. Yao K, He L, Gan Y, Zeng Q, Dai Y, Tan J. MiR-186 suppresses the growth and metastasis of bladder cancer by targeting NSBP1. Diagn Pathol. 2015;10:146 pubmed publisher
    ..Our data first time identified miR-186 as the upstream regulator of NSBP1 and also suggest miR-186-suppressed NSBP1 as a novel therapeutic approach for bladder cancer. ..
  5. Sha W, Shen L, Zhou L, Xu D, Lu G. Down-regulation of miR-186 contributes to podocytes apoptosis in membranous nephropathy. Biomed Pharmacother. 2015;75:179-84 pubmed publisher
    ..We revealed that TLR4 is involved in the regulation of miR-186 expression, and the anti-apoptotic effect of miR-186 on podocytes is correlated with P2×7 regulation. ..
  6. Zhou L, Qi X, Potashkin J, Abdul Karim F, Gorodeski G. MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of instability sites at the 3'-untranslated region of the gene that decrease steady-state levels of the transcript. J Biol Chem. 2008;283:28274-86 pubmed publisher
    ..These data suggest that increased expression of miR-186 and miR-150 in cancer epithelial cells decreases P2X7 mRNA by activation of miR-186 and miR-150 instability target sites located at the 3'-UTR-P2X7. ..
  7. Huang T, She K, Peng G, Wang W, Huang J, Li J, et al. MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer. Int J Oncol. 2016;49:1437-44 pubmed publisher
    ..Therefore, miR-186-MAP3K2 may represent a new and useful potential clinical treatment and diagnosis target for NSCLC. ..
  8. Liu Z, Zhang G, Yu W, Gao N, Peng J. miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1. Biochem Biophys Res Commun. 2016;469:692-7 pubmed publisher
    ..Our collective results clearly indicate that miR-186 functions as a tumor suppressor in MM, supporting its potential as a therapeutic target for the disease. ..
  9. Lee Y, Kim S, Bae Y. Upregulation of miR-760 and miR-186 is associated with replicative senescence in human lung fibroblast cells. Mol Cells. 2014;37:620-7 pubmed publisher
  10. Zhang T, Wang Y, Yang D, Yao D, Yang L, Zhou J, et al. Down-Regulation of miR-186 Correlates with Poor Survival in de novo Acute Myeloid Leukemia. Clin Lab. 2016;62:113-20 pubmed
    ..017 and 0.023, respectively). Our study suggests that miR-186 down-regulation is a frequent event and predicts poor prognosis in de novo AML patients. ..
  11. Shaer A, Azarpira N, Karimi M. Differentiation of human induced pluripotent stem cells into insulin-like cell clusters with miR-186 and miR-375 by using chemical transfection. Appl Biochem Biotechnol. 2014;174:242-58 pubmed publisher
    ..This work provides a new approach by using patient-specific iPSCs for ?-cell replacement therapy in diabetic patients. ..
  12. Ma Y, Wang P, Xue Y, Qu C, Zheng J, Liu X, et al. PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186. Tumour Biol. 2017;39:1010428317694326 pubmed publisher
    ..Therefore, PVT1 and miR-186 can provide new therapeutic targets for future anti-angiogenic treatment of glioma. ..
  13. Wu J, Song J, Wang C, Niu D, Li H, Liu Y, et al. Identification of serum microRNAs for cardiovascular risk stratification in dyslipidemia subjects. Int J Cardiol. 2014;172:232-4 pubmed publisher
  14. Wang H, Shen Q, Zhang X, Yang C, Cui S, Sun Y, et al. The Long Non-Coding RNA XIST Controls Non-Small Cell Lung Cancer Proliferation and Invasion by Modulating miR-186-5p. Cell Physiol Biochem. 2017;41:2221-2229 pubmed publisher
    ..Together, our data revealed that XIST knockdown confers suppressive function in NSCLC and XIST may be a novel therapeutic marker in this disease. ..
  15. Islam F, Gopalan V, Vider J, Wahab R, Ebrahimi F, Lu C, et al. MicroRNA-186-5p overexpression modulates colon cancer growth by repressing the expression of the FAM134B tumour inhibitor. Exp Cell Res. 2017;357:260-270 pubmed publisher
    ..Reduced cancer cells growth followed by inhibition of miR-186-5p highlights the potential of miR-186-5p inhibitor as a novel strategy for targeting colorectal cancer initiation and progression. ..
  16. Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, Neukam F, et al. miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 2014;31:1429-36 pubmed publisher
    ..02) and clinical stage (p=0.04) were indicated. Aberrant expression levels of miR-186, miR-494 and miR-3651 in whole blood samples of OSCC patients may provide the possibility to establish a minimally invasive screening method for OSCC. ..
  17. Zhu X, Shen H, Yin X, Long L, Xie C, Liu Y, et al. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene. 2016;35:323-32 pubmed publisher
    ..Collectively, these findings implicate miR-186 as an attractive candidate for overcoming chemoresistance in ovarian cancer therapy. ..
  18. Sun P, Hu J, Xiong W, Mi J. miR-186 regulates glycolysis through Glut1 during the formation of cancer-associated fibroblasts. Asian Pac J Cancer Prev. 2014;15:4245-50 pubmed
    ..These observations suggest that miR-186 plays important roles in glycolysis regulation as well as cell cycle checkpoint activation. ..
  19. Cao C, Sun D, Zhang L, Song L. miR-186 affects the proliferation, invasion and migration of human gastric cancer by inhibition of Twist1. Oncotarget. 2016;7:79956-79963 pubmed publisher
    ..Thus, miR-186 may be served as a candidate prognostic biomarker and target for new therapies in human gastric cancer. ..
  20. Zhao X, Wang Y, Deng R, Zhang H, Dou J, Yuan H, et al. miR186 suppresses prostate cancer progression by targeting Twist1. Oncotarget. 2016;7:33136-51 pubmed publisher
    ..We find that a key miRNA--miR186 is significantly reduced in M12 compared to that in P69...
  21. Terzuoli E, Donnini S, Finetti F, Nesi G, Villari D, Hanaka H, et al. Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and -186 expression: Novel mechanism of VEGF modulation in prostate cancer. Oncotarget. 2016;7:44350-44364 pubmed publisher
  22. Zheng J, Li X, Wang P, Liu X, Xue Y, Hu Y, et al. CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186. Oncotarget. 2015;6:25339-55 pubmed publisher
    ..In conclusion, CRNDE played an oncogenic role of GSCs through the negative regulation of miR-186. Both CRNDE and miR-186 could be regarded as potential targets in the glioma therapy. ..
  23. Li C, Gao Y, Li Y, Ding D. TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. Biochem Biophys Res Commun. 2017;491:552-557 pubmed publisher
    ..Extensively, our study also showed that CPEB2 was the direct target of miR-186 in colorectal cancer cells. Taken together, our study suggests that lncRNA TUG1 mediates MTX resistance in colorectal cancer via miR-186/CPEB2 axis. ..
  24. Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers. 2009;27:255-68 pubmed publisher
    ..Finally, qRT-PCR analysis confirmed dysregulation of 7 miRNAs, miR-150, miR-186, miR-210, miR-451, and muscle-specific, miR-1 and miR-133a/b; all of these are believed to be involved in various physiological and pathological processes. ..
  25. Ye J, Zhang Z, Sun L, Fang Y, Xu X, Zhou G. miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). Mol Biosyst. 2016;12:3417-3424 pubmed
    ..miR-186 may represent a new therapeutic target for the improvement of the clinical outcome in NSCLC. ..
  26. Dang R, Liu F, Li Y. Circular RNA hsa_circ_0010729 regulates vascular endothelial cell proliferation and apoptosis by targeting the miR-186/HIF-1? axis. Biochem Biophys Res Commun. 2017;490:104-110 pubmed publisher
    ..Overall, the present study identifies the crucial regulation of hsa_circ_0010729 on vascular endothelial cell proliferation and apoptosis via targeting miR-186/HIF-1? axis. ..
  27. Lan T, Yan X, Li Z, Xu X, Mao Q, Ma W, et al. Long non-coding RNA PVT1 serves as a competing endogenous RNA for miR-186-5p to promote the tumorigenesis and metastasis of hepatocellular carcinoma. Tumour Biol. 2017;39:1010428317705338 pubmed publisher
    ..Taken together, plasmacytoma variant translocation 1 served as an endogenous sponge for miR-186-5p to reduce its inhibiting effect on yes-associated protein 1 and thus promoted the tumorigenesis of hepatocellular carcinoma. ..
  28. Wang Y, Chen F, Zhao M, Yang Z, Li J, Zhang S, et al. The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186. J Biol Chem. 2017;292:15395-15407 pubmed publisher
  29. Zhang Z, Bai Z, Wang X, Bai L, Miao F, Pei H. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells. PLoS ONE. 2015;10:e0118814 pubmed publisher
    ..These two miRNAs can be used as markers for clinical diagnosis and prognosis, and they represent therapeutic targets for PDAC. ..